PI3K signaling pathway targeting by using different molecular approaches to treat cancer

doi:10.5246/jcps.2017.09.070

中国药学(英文版) ›› 2017, Vol. 26 ›› Issue (9): 621-634.DOI: 10.5246/jcps.2017.09.070

• 【综述】 • 下一篇

PI3K signaling pathway targeting by using different molecular approaches to treat cancer

Mohammad Rashid^1*, Shahid Karim¹, Babar Ali¹, Shamshir Khan¹, Makhmur Ahmad¹, Asif Husain², Ravinesh Mishra³

1. Department of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy and Dentistry, Buraydah Colleges, Al-Qassim 31717, Kingdom of Saudi Arabia
2. Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Jamia Hamdard (Hamdard University), Hamdard Nagar, New Delhi-110062, India
3. Institute of Pharmacy & Emerging Sciences, Baddi University of Emerging Science & Technology, Makhnumajra, Baddi, Solan-173205, Himachal Pradesh, India

收稿日期:2017-04-23 修回日期:2017-06-19 出版日期:2017-09-30 发布日期:2017-08-25
通讯作者: Tel.: +966-577148790, E-mail: rashidpharm2008@gmail.com

PI3K signaling pathway targeting by using different molecular approaches to treat cancer

Mohammad Rashid^1*, Shahid Karim¹, Babar Ali¹, Shamshir Khan¹, Makhmur Ahmad¹, Asif Husain², Ravinesh Mishra³

1. Department of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy and Dentistry, Buraydah Colleges, Al-Qassim 31717, Kingdom of Saudi Arabia
2. Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Jamia Hamdard (Hamdard University), Hamdard Nagar, New Delhi-110062, India
3. Institute of Pharmacy & Emerging Sciences, Baddi University of Emerging Science & Technology, Makhnumajra, Baddi, Solan-173205, Himachal Pradesh, India

Received:2017-04-23 Revised:2017-06-19 Online:2017-09-30 Published:2017-08-25
Contact: Tel.: +966-577148790, E-mail: rashidpharm2008@gmail.com

摘要/Abstract

摘要：

Recent evidence of research has been proposed that the phosphoinositide 3-kinase (PI3K) pathway is noticeable target for searching novel anticancer agents. The phosphoinositide 3-kinase (PI3K) is accountable for harmonizing a diverse range of cell functions, such as transcription, proliferation, cell survival, cell growth, degranulation, vesicular trafficking and cell migration, which are mostly involved in carcinogenesis. Particularly, PI3K-mediated signaling molecules and its effects on gene expression contribute to tumorigenesis. PI3Ks generally are grouped into three distinct classes: I, II and III according to their structure and function. The class IA of PI3K includes an alpha, beta or delta p110 catalytic subunit (p110α, p110β, or p110γ), which are associatedwith the activation of RTKs. Mutations in PIK3CA, the gene encoding the p110α catalytic subunit of PI3K, have just been recognizedas novel mechanisms of inducing oncogenic PI3K signaling. Therefore, the class IA PI3K is the only one of most evidently implicated in cancer. The PI3K pathway is mostly mutated in more cancer patients compared with normal person, making it an eye-catching molecular target for analyses based on inhibitor molecule. In this article, we highlighted the signaling effects and regulation pathway of PI3K involved in the development and survival of tumor cells. The consequence and intricacy of PI3K pathway made it an essential beneficial target for cancer treatment.

关键词: PI3K, AKT, mTOR, PDK-1, Tumor suppressor PTEN, Signal pathway

Abstract:

Key words: PI3K, AKT, mTOR, PDK-1, Tumor suppressor PTEN, Signal pathway

中图分类号:

R965

Supporting:

Mohammad Rashid, Shahid Karim, Babar Ali, Shamshir Khan, Makhmur Ahmad, Asif Husain, Ravinesh Mishra. PI3K signaling pathway targeting by using different molecular approaches to treat cancer[J]. 中国药学(英文版), 2017, 26(9): 621-634.

参考文献

[1] Vogt, P.K.; Kang, S.; Elsliger, M.A. Trends Biochem. Sci. 2007, 32, 342–349.

[2] Hennessy, B.T.; Smith, D.L.; Ram, P.T.; Lu, Y.; Mills, G.B. Nat. Rev. Drug. Discov. 2005, 4, 988–1004.

[3] Katso, R. Annu. Rev. Cell. Dev. Biol. 2001, 17, 651–675.

[4] Lawlor, M. J. Cell. Sci. 2001, 114, 2903–2910.

[5] Parsons, R.S. Cell. Dev. Biol. 2004, 15, 171–176.

[6] Rameh, L.E.; Cantley, L.C. J. Bio. Chem. 1999, 274, 8347–8350.

[7] Shaw, R.J.; Cantley, L.C. Nature. 2006, 441, 424–430.

[8] Vimalanathan, A.B.; Raja, A.K.; Tyagi, M.G. Bio. Med. 2009, 1, 203–215.

[9] Philip, A.J.; Campbell, I.G.; Lect, C.; Vincan, E.; Rockman, S.P.; Whitehead, R.H.; Thomas, R.J.; Philip, W.A. Cancer Res. 2001, 61, 7426–7429.

[10] Anderson, K.E.; Jackson, S.P. Cell. Biol. 2003, 35, 1028–1033.

[11] Liu, P. Nat. Rev. Drug. Discov. 2009, 8, 627–644.

[12] Ikeda, H. Blood. 2010, 116, 1460–1468.

[13] Yu, J.; Zhang, Y.; McIlroy, J.; Rordorf, N.T.; Orr, G.A.; Backer, J.M. Mol. Cell. Bio. 1998, 18, 1379–1387.

[14] Huang, C.H.; Mandelker, D.; Gabelli, S.B.; Amzel, L.M. Cell. Cycl. 2008, 7, 1151–1156.

[15] Luo, J.; Manning, B.D.; Cantley, L.C. Cancer. Cell. 2003, 4, 257–262.

[16] Wennan, Z.; Yuling, Q.; Dexin, K. Acta. Pharm. Seuc. B. 2017, 7, 27–37.

[17] Carpenter, C.L.; Duckworth, B.C.; Auger, K.R.; Cohen, B.; Schaffhausen, B.S.; Cantley, L.C. J. Biol. Chem. 1990, 265, 19704–19711.

[18] Carpenter, C.L.; Auger, K.R.; Chanudhuri, M.; Yoakim, M.; Schaffhausen, B.; Shoelson, S.; Cantley, L.C. J. Biol. Chem. 1993, 268, 9478–9483.

[19] Songyang, Z.; Shoelson, S.E.; Chaudhuri, M.; Gish, G.; Pawson, T.; Haser, W.G.; King, F.; Roberts, T.; Ratnofsky, S.; Lechleider, R.J. Cell. 1993, 72, 767–778.

[20] Yoakim, M.; Hou, W.; Songyang, Z.; Liu, Y.; Cantley, L.; Schaffhausen, B. Mol. Cell. Bio. 1994, 14, 5929–5938.

[21] Backer, J.M. Biochem. J. 2008, 410, 1–17.

[22] Saito, M.; Okamoto, A.; Kohono, T.; Takakura, S.; Shinnozki, H.; Isonishi, S.; Yasuhara, T.; Yoshimura, T.; Ohtake, Y.; Ochiai, K.; Yotota, J.; Tanaka, T. Int. J. Cancer. 2000, 85, 160–165.

[23] Vanhaesebroeck, B.; Ali, K.; Bilancio, A.; Geering, B.; Foukas, L.C. Trends. Biochem. Sci. 2005, 30, 194–204.

[24] Garcia, E.C.; Sellers, W.R. Oncogene. 2008, 27, 5511–5526.

[25] Cantley, L.C. Science. 2002, 296, 1655–1657.

[26] Osaki, M.; Oshimura, M.; Ito, H. Apoptosis. 2004, 9, 667–676.

[27] Samuels, Y. Science. 2004, 304, 554–567.

[28] Leevers, S.J.; Vanhaesebroeck, B.; Waterfield, M.D. Current Opinion in Cell Bio. 1999, 11, 219–225.

[29] Toker, A.; Cantley, L.C. Nature. 1997, 387, 673–676.

[30] Camillo, P.; Chiara, P.; Alessandra, M. Front. Oncol. 2014, 4, 1–11.

[31] Bellacosa, A.; Feo, D.; Godwin, A.K.; Bell, D.W.; Cheng, J.Q.; Altomarc, D.A.; Wan, M.; Dubeau, L.; Scambia, G.; Masciullo, V. Int. J. Cancer. 1995, 64, 280–285.

[32] Peltier, J.; O'Neill, A.; Schaffer, D.V. Dev. Neurobio. 2007, 67, 1348–1361.

[33] Nader, C.; Suzanne, J.; Baker, N. Annu. Rev. Pathol. 2009, 4, 127–150.

[34] Huang, J.; Kontos, C.D. J. Biol. Chem. 2002, 277, 10760–10766.

[35] Enomoto, A.; Murakami, H.; Asai, N. Cell. 2005, 9, 389–402.

[36] Rafalski, V.A.; Brunet, A. Prog. Neurobiol. 2011, 93, 182–203.

[37] Huang, C.H.; Mandelker, D.; Schmidt K.O.; Samuels, Y.; Velculescu, V.E. Science. 2007, 318, 1744–1748.

[38] Ali, I.U.; Schrim, L.M.; Dean, M. J. Natl. Cancer. Inst. 1999, 91, 1922–1932.

[39] Miled, N.; Yan, Y.; Hon, W.C.; Perisic, O.; Zvelebil, M. Science. 2007, 317, 239–242.

[40] Yuan, T.L.; Cantley, L.C. Oncogene. 2008, 27, 5497–5510.

[41] Sun, M.; Wang, G.; Paciga, J.E.; Feldman, R.I.; Yun, Z.Q.; Ma, X.; Shelly, S.A.; Jove, R.; Tsichlis, P.N.; Nicosia, S.V.; Cheng, J.Q. Am. J. Pathol. 2001, 159, 431–437.

[42] Zhang, L.; Yng, N.; Kataros, D.; Huang, W.; Park, J.W.; Fracchioli, S.; Vezzani, C.; Rigault, D.L.; Longrais, I.A.; Yao, W.; Rubin, S.C.; Coukos, G. Cancer Res. 2003, 63, 4225–4231.

[43] Zhao, J.J. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 18443–18448.

[44] Stokoe, D. Expert. Rev. Mol. Med. 2005, 7, 1–22.

[45] Courtney, K. J. Clin. Oncol. 2010, 28, 1075–1083.

[46] Dexin, K.; Takao, Y. Cancer. Sci. 2008, 99, 1734–1740.

[47] Mills, G.B.; Lu, Y.; Fang, X.; Wang, H.; Eder, A.; Mao, M.; Swaby, R.; Cheng, K.W.; Stokoe, D.; Siminovitch, K.; Jaffe, R.; Gray, J. Semin. Oncol. 2001, 28, 125–141.

[48] Maehama, T.; Dixon, J.E. J. Biol. Chem. 1998, 273, 13375–13378.

[49] Myers, M.P.; Pass, I.; Batty, I.H.; Van, D.K.J.; Stolarov, J.P. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 13513–13518.

[50] Su, J.D.; Mayo, L.D.; Donner, D.B.; Durden, D.L. Cancer Res. 2003, 63, 3585–3592.

[51] Scheid, M.P.; Woodgett, J.R. Nat. Rev. Mol. Cell. Biol. 2001, 2, 760–780.

[52] Hay, N.; Sonenberg, N. Genes. Dev. 2004, 18, 1926–1945.

[53] King, D.; Yeomanson, D.; Bryant, H.E. J. Pediat. Hematol. Oncol. 2015, 37, 245–251.

[54] Knight, Z.A.; Shokat, K.M. Biochem. Soc. Trans. 2007, 35, 245–249.

[55] Lu, Y.; Wang, H.; Mills, G.B. Rev. Clin. Exp. Hematol. 2003, 7, 205–228.

[56] Pixu, L.; Hailing, C.; Thomas, M.R.; Jean, J.Z. Nat. Rev. Drug. Discov. 2011, 8, 627–644.

[57] Stein, R.C.; Waterfield, M.D. Mol. Med. Today. 2000, 6, 347–357.

[58] Sabatini, D.M. Nat. Rev. Cancer. 2006, 6, 729–734.

[59] Sawyers, C.L. Cancer. 2002, 2, 489–501.

[60] Loewith, R.; Jacinto, E.; Wullschleger, S.; Lorberg, A.; Crespo, J.L.; Bonenfant, D.; Oppliger, W.; Jenoe, P.; Hall, M.N. Mol. Cell. 2002, 10, 457–468.

[61] Okkenhaug, K. Ann. Rev. Immun. 2013, 31, 675–704.

[62] Kang, S.; Bader, A.G.; Vogt, P.K. Proc. Natl. Acad. Sci. USA. 2005, 102, 802–807.

[63] Manning, B.D.; Cantley, L.C. Cell. 2007, 129, 1261–1274.

[64] Thomas, R.K.; Baker, A.C.; Debiasi, R.M.; Winckler, W.; Laframboise, T.; Lin, W.M.; Wang, M.; Feng, W.; Zander, T.; Mac-Conaill, L. Nat. Genet. 2007, 39, 347–351.

[65] Whyte, D.B.; Holbeck, S.L. Biochem. Biophys. Res. Commun. 2006, 340, 469–475.

[66] John, J.H. Saudi. Pharma. J. 2012, 20, 103–123.

[67] Forsythe, J.A.; Jiang, B.H.; Iyer, N.V. Mol. Cell. Biol. 1996, 16, 4604–4613.

[68] Xu, C.; Zhou, Q.; Wu, Y. J. Hematol. Oncol. 2012, 5, 62.

[69] Man, H.Y.; Wang, Q.; Lu, W.Y.; Ju, W.; Ahmadian, G.; Liu, L.; D’Souza, S.; Wong, T.P.; Taghibiglou, C.; Lu, J.; Becker, L.E.; Pei, L.; Liu, F.; Wymann, M.P.; MacDonald, J.F.; Wang, Y.T. Neuron. 2003, 38, 611–624.

[70] Sui, L.; Wang, J.; Li, B.M. Learn. Mem. 2008, 15, 762–776.

[71] Martin, D.E.; Soulard, A.; Hall, M.N. Cell. 2004, 119, 969–979.

[72] Rodriguez, V.P.; Sabatier, C.; McCormick, F. Mol. Cell. Biol. 2004, 24, 4943–4954.

[73] Cully, M.; You, H.; Levine, A.J.; Mak, T.W. Nat. Rev. Cancer. 2006, 6, 184–192.

[74] Guertin, D.A.; Stevens, D.M.; Thoreen, C.C.; Burds, A.A.; Kalaany, N.Y.; Moffat, J.; Brown, M.; Fitzgerald, K.J.; Sabatini, D.M. Dev. Cell. 2006, 11, 859–871.

[75] Ojeda, L.; Gao, J.; Hooten, K.G.; Wang, E.; Thonhoff, J.R.; Dunn, T.J.; Gao, T.; Wu, P. https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC3160859. PLoS ONE. 2011, 6, 214–234.

[76] Kalaany, N.Y.; Sabatini, D.M. Nature. 2009, 458, 725–731.

[77] Jacinto, E.; Loewith, R.; Schmidt, A.; Lin, S.; Ruegg, M.A.; Hall, A.; Hall, M.N. Nat. Cell. Biol. 2004, 6, 1122–1128.

[78] Giles, F.J.; Albitar, M. Curr. Mol. Med. 2005, 5, 653–661.

[79] Sarbassov, D.D.; Guertin, D.A.; Ali, S.M.; Sabatini, D.M. Science. 2005, 307, 1098–1101.

[80] Brugarolas, J.; Lei, K.; Hurley, R.L.; Manning, B.D.; Reiling, J.H.; Hafen, E.; Witters, L.A.; Ellisen, L.W.; Kaelin, W.G. Genes. Dev. 2004, 18, 2893–2904.

[81] Engelman, J.A.; Luo, J.; Cantley, L.C. Nat. Rev. Genet. 2006, 7, 606–619.

[82] Jiang, B.H.; Jiang, G.; Zheng, J.Z.; Lu, Z.; Hunter, T.; Vogt, P.K. Cell. Growth. Differ. 2001, 12, 363–369.

[83] Semenza, G.L. Nat. Rev. Cancer. 2003, 3, 721–732.

[84] Arcaro, A. Biochem. J. 1993, 296, 297–301.

[85] Bauer, D.E.; Harris, M.H.; Plas, D.R., Lum, J.J.; Hammerman, P.S.; Rathmell, J.C.; Riley, J.L.; Thompson, C.B. FASEB J. 2004, 18, 1303–1305.

[86] Akintunde, A.; Parthu, A.; Muhammad, F.; Yongping, S.; Delong, L. J. Hemat. Onco. 2013, 6, 88–105.

[87] Domin, J.; Pages, F.; Volinia, S.; Rittenhouse, S.E.; Zvelebil, M.J.; Stein, R.C.; Waterfield, M.D. Biochem. J. 1997, 326, 139–147.

[88] Fernanda, M.; Robert, S. Transl. Cancer. Res. 2015, 4, 97–106.

[89] Powis, G.; Bonjouklian, R.; Berggren, M.M.; Gallegos, A.; Abraham, R.; Ashendel, C.; Zalkow, L.; Matter, W.F.; Dodge, J.; Grindey, G.; Vlahos, C.J. Cancer. Res. 1994, 54, 2419–2423.

[90] Irene, B.; Lillian, L.S. Brana Siu BMC Med. 2012, 10, 1741–7015.
[91] Wu, P.; Hu, Y.Z. Curr. Med. Chem. 2010, 17, 4326–4341.

PI3K signaling pathway targeting by using different molecular approaches to treat cancer

PI3K signaling pathway targeting by using different molecular approaches to treat cancer

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 3

编辑推荐

Metrics

本文评价

[1]	郑吴殷晓, 李海平, 罗来春, 胡春玲, 尤朋涛. TOPC通过抑制PI3K/AKT/mTOR通路, 抑制miR-210, Atg7诱导H1975细胞凋亡[J]. 中国药学(英文版), 2023, 32(11): 881-892.
[2]	孙志勇, 高淑丽, 张阳, 薛刚强, 苑子林, 王少男. 基于网络药理学和分子对接技术研究蒲公英治疗乳腺增生的潜在机制[J]. 中国药学(英文版), 2023, 32(11): 893-910.
[3]	焦佩丽, 李奕言, 吴兴, 王昱曦, 毛蓓蓓, 金宏威, 张礼和, 张亮仁, 刘振明. 基于结构设计的新型mTOR抑制剂的抗宫颈癌活性研究[J]. 中国药学(英文版), 2020, 29(9): 603-616.